[1]何凯骅,章 斌,陈志强,等.血清sTg和TgAb水平监测甲状腺乳头状癌患者低剂量碘-131疗效的研究[J].现代检验医学杂志,2018,33(06):142-145.[doi:10.3969/j.issn.1671-7414.2018.06.037]
　HE Kai-hua,ZHANG Bin,CHEN Zhi-qiang,et al.Value for Clinical Effects of Low-dose 131I Therapy in Patients with Papillary Thyroid Carcinoma by Monitoring Serum Stimulated Thyroglobulin and Thyroglobulin Antibody[J].Journal of Modern Laboratory Medicine,2018,33(06):142-145.[doi:10.3969/j.issn.1671-7414.2018.06.037]
点击复制

血清sTg和TgAb水平监测甲状腺乳头状癌患者低剂量碘-131疗效的研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年06期
页码:
142-145
栏目:
检验与临床
出版日期:
2018-12-24

文章信息/Info

Title:
Value for Clinical Effects of Low-dose 131I Therapy in Patients with Papillary Thyroid Carcinoma by Monitoring Serum Stimulated Thyroglobulin and Thyroglobulin Antibody
文章编号:
1671-7414(2018)06-142-04
作者:
何凯骅1; 章 斌1; 陈志强1; 何 杨2; 桑士标1
1.苏州大学附属第一医院核医学科,江苏苏州 215006; 2.江苏省血液研究所,江苏苏州 215006
Author(s):
HE Kai-hua1; ZHANG Bin1; CHEN Zhi-qiang1; HE Yang2; SANG Shi-biao1
1.Department of Nuclear Medicine,the First Affiliated Hospitalof Soochow University,Jiangsu Suzhou 215006,China; 2.Jiangsu Blood Institute,Jiangsu Suzhou 215006,China
关键词:
刺激性甲状腺球蛋白;  甲状腺乳头状癌;  碘-131;  治疗;  低剂量
分类号:
R736.1; R730.43
DOI:
10.3969/j.issn.1671-7414.2018.06.037
文献标志码:
A
摘要:
目的 探讨甲状腺乳头状癌患者在低剂量碘-131清除残留甲状腺组织(清甲)治疗前后,血清刺激性甲状腺球蛋白(stimulated thyroglobulin,sTg)和甲状腺球蛋白抗体(thyroglobulin antibody,TgAb)水平及其变化趋势对清甲疗效的判断价值。方法 选取2014年5月～2016年12月76例甲状腺乳头状癌患者行1.11GBq 131I清甲治疗和碘-131全身及颈部断层显像,治疗前检测患者sTg-1和TgAb-1水平。第一次清甲治疗半年后复查sTg-2和TgAb-2水平,sTg-2 >1 μg/L患者再行1.11GBq131I清甲治疗和碘-131显像。第二次清甲治疗后半年,患者复查sTg和TgAb水平并行185 MBq碘-131显像判断清甲治疗疗效。以(sTg-2-sTg-1,△sTg)/sTg-1百分比值(%)代表sTg变化趋势,采用单因素方差分析或配对t检验比较转移组、清甲成功组及正常甲状腺残留组各组间sTg值及△sTg/sTg-1比值。结果 两次清甲治疗后显像发现转移患者20例(26.32%,2例肺部转移,18例淋巴结转移); 清甲成功率合计为83.93%(47/56); 残留率合计为16.07%(9/56)。转移组sTg-1值均高于无转移组,差异有统计学意义(F=5.800,P<0.05)。第二次显像发现转移组sTg-2比sTg-1升高比例为55.56%(5/9); sTg-2降低患者中转移组的△sTg /sTg-1比值较未发现转移组低,差异有统计学意义(F=3.393,P<0.05)。结论 血清sTg和TgAb水平在判断低剂量清甲治疗后是否存在转移或清甲是否成功有确切的临床应用价值。
Abstract:
Objective To investigate the levels and variation tendency of stimulated thyroglobulin(sTg)and thyroglobulin antibody(TgAb)before and after low-dose 131I therapy in papillary thyroid carcinoma(PTC),and monitor the predictive value of sTg for the efficacy of 131I therapy.Methods From May 2014 to Dec 2016,a total of 76 PTCpatients(28 males,48 females),average age(39.10±11.95)years,were received 1.11GBq 131I therapy,and 131I whole body and neck tomography imagingwere performed.sTg-1 and TgAb-1 levels were measured before treatment,and sTg-2 and TgAb-2 levels were measured half a year later after first treatment.If sTg-2>1 μg/L,patients were received 1.11GBq 131I therapy again,andalso 131I whole body and neck tomography imaging were performed.Half a year later after second treatment,sTg3 and TgAb3 levels were measured,and 185 MBq 131I whole body scan and neck tomography imaging were performed to evaluate treatment effect.(sTg-2-sTg-1,△sTg)/sTg-1 defined as index of variation tendency.Results After the treatment of two times 131I therapy,a total of 20 cases(26.32%,including 2 patients with pulmonary metastasis and 18 patients with lymph node metastasis)of metastatic patients were detected by 131I imaging.The rate of successful thyroid remnant ablation was 83.93%(47/56 cases),and the residual rate was 16.07%(9/56).Thelevels of sTg in metastasis group were high than non-metastasis groups,and there were statistical differences between these groups(F=5.800,P<0.05).The increase ratio of sTg-2 value compared sTg-1 was 55.56%(5/9)in metastasisgroup detected by the second time 131I imaging.△sTg/sTg-1 values of patients in normal thyroid group with sTg-2 reduction was low than non-metastasis groups,and there were statistical differences between these groups(F=3.393,P<0.05).Conclusion The levels of serum sTg and TgAb could be used in clinic to predict the efficacy of 131I therapy in PTC patients.

参考文献/References:

[1] 郑向前,侯秀坤,高 明.2017年第二版NCCN甲状腺肿瘤指南解读[J].中国肿瘤临床,2018,45(1):14-17.
Zheng XQ,Hou XK,Gao M.Interpretation of the second edition of theNCCN guidelines for thyroid cancer in 2017[J].Chinese Journal of Clinical Oncology,2018,45(1):14-17.
[2] Pryma DA,Mandel SJ.Radioiodine therapy for thyroid cancer in the era ofrisk stratification and alternative targeted therapies[J].Journal of NuclearMedicine Official Publication Society of Nuclear Medicine,2014,55(9):1485-1491.
[3] 中华医学会核医学分会.131I治疗分化型甲状腺癌指南(2014版)[J].中华核医学与分子影像杂志,2014,34(4):264-278.
Chinese Society of Nuclear Medicine.Clinical guidelines for 131I therapy of differentiated thyroid cancer(2014)[J].Chinese Journal of Nuclear Medicine and Molecular Imaging,2014,34(4):264-278.
[4] Haugen BR,Alexander EK,Bible KC,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26(3):1-133.
[5] 徐凌云,谭 建,张桂芝,等.甲状腺乳头状癌131I清甲治疗前后刺激性甲状腺球蛋白对清甲疗效的预测价值[J].中华核医学与分子影像杂志,2018,38(3):156-159.
Xu LY,Tan J,Zhang GZ,et al.Predictive value of the stimulated thyroglobulin before and after 131I therapy for curative effect inpatients with papillary thyroid carcinoma[J].Chinese Journal of Nuclear Medicine and Molecular Imaging,2018,38(3):156-159.
[6] 郑立春,张 腾,胡厚洋,等.非远处转移分化型甲状腺癌低剂量131I清甲治疗疗效分析[J].中华核医学与分子影像杂志,2018,38(3):160-163.
Zheng LC,Zhang T,Hu HY,et al.Ablation efficacy for non-distant metastases differentiated thyroid carcinoma with low-dose 131I[J].Chinese Journal of Nuclear Medicine andMolecular Imaging,2018,38(3):160-163.
[7] 林岩松.有关分化型甲状腺癌核医学相关诊治的指南更新[J].中华核医学与分子影像杂志,2018(3):172-177.
Lin YS.Updates regarding nuclear medicine in guidelines for differentiated thyroid carcinoma management[J].Chinese Journal of Nuclear Medicine and Molecular Imaging,2018,38(3):172-177.

备注/Memo

备注/Memo:
作者简介:何凯骅(1991-),男,本科,检验技师,主要从事化学发光免疫研究,Tel:0512-67973116,E-mail:sdfyyhkh@163.com。
通讯作者:章 斌(1972-),男,博士,主任医师,主要从事核医学相关研究,E-mail:zbnuclmd@126.com。
更新日期/Last Update: 2018-11-30